The life sciences industry is on the verge of challenges unlike any in its history:
- In large pharmaceutical companies, revenues are at-risk to patent expirations, research and development productivity is down, and the potential for new blockbusters is increasingly scarce.
- Biopharmaceutical products seem ready to assume center-stage, yet the sector’s ability to yield blockbusters remains unproven, and the complexity in manufacturing and distribution complicates the profit picture.
- Pharmaceutical and medical device hybrids show great potential, but market entry is costly and risky, and safety issues cloud the horizon.
Economics and demographics add further complexities—back office costs are high, regulatory oversight is heavy, sales force productivity has reached a plateau, and operational efficiency has become a major concern.
AlixPartners—For when it really matters
At AlixPartners, we have unmatched capabilities to assist you in facing these looming challenges. We relentlessly focus on both the top and bottom lines, and our “skin-in-the-game” compensation model holds us very much accountable for delivering quantifiable value to your income statement and balance sheet. We specialize in resolving urgent, high-impact business challenges, including: